1338709-05-9Relevant articles and documents
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
Aoki, Toshiaki,Yoshizawa, Hidenori,Yamawaki, Kenji,Yokoo, Katsuki,Sato, Jun,Hisakawa, Shinya,Hasegawa, Yasushi,Kusano, Hiroki,Sano, Masayuki,Sugimoto, Hideki,Nishitani, Yasuhiro,Sato, Takafumi,Tsuji, Masakatsu,Nakamura, Rio,Nishikawa, Toru,Yamano, Yoshinori
, p. 847 - 868 (2018/07/03)
The structure-activity relationship (SAR) for a novel series of catechol conjugated siderophore cephalosporins is described with their in vitro activities against multi-drug resistant Gram-negative pathogens including Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia and Enterobacteriaceae. Cefiderocol (3) was one of the best molecules which displayed well-balanced and potent activities against multi-drug resistant Gram-negative pathogens including carbapenem resistant bacteria among the prepared compounds with the modified C-7 side chain and the modified C-3 side chain. Cefiderocol (3) is a highly promising parenteral cephalosporin for the treatment of multi-drug resistant Gram-negative infection.
